-+ 0.00%
-+ 0.00%
-+ 0.00%

Tevogen advances TVGN 489 toward next clinical phase for Long COVID with 65% U.S. HLA eligibility coverage

Reuters·03/11/2026 19:28:55

Please log in to view news